aP	Acellular pertussis
aPV	Acellular pertussis vaccine
ANOVA	Analysis of variance
B1917	Bordetella pertussis strain B1917
BG	Bordet–Gengou
BPSM	Bordetella pertussis streptomycin- and nalidixic acid-resistant derivative of Tohama-1
BPZE1	Live attenuated intranasal Bordetella pertussis vaccine candidate
BSA	Bovine serum albumin
C’	Complement
CFU	Colony-forming unit
CI	Confidence interval
CLSI	Clinical and Laboratory Standards Institute
CO2	Carbon dioxide
CV	Coefficient of variation
D29	Day 29 post-vaccination
ECL	Electrochemiluminescence
FHA	Filamentous hemagglutinin
FIM	Fimbriae
GCLP	Good Clinical Laboratory Practice
GMT	Geometric mean titer
GMR	Geometric mean ratio
HBSS	Hanks’ balanced salt solution
ICH	International Conference for Harmonisation
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IU	International unit
LLOQ	Lower limit of quantitation
LLL	Lower limit of linearity
LLP	Lower limit of precision
MAC	Membrane attack complex
NIBSC	National Institute for Biological Standards and Control
PRN	Pertactin
PRN+	Pertactin-positive
PRN−	Pertactin-negative
QC	Quality control
R2	Coefficient of determination
RIVM	National Institute for Public Health and the Environment (The Netherlands)
RT	Room temperature
SBA	Serum bactericidal assay
SD	Standard deviation
SI	Supplementary Information
Tdap	Tetanus–diphtheria–acellular pertussis vaccine
ULOQ	Upper limit of quantitation
ULL	Upper limit of linearity
ULP	Upper limit of precision
WCE	Whole-cell extract
wPV	Whole-cell pertussis vaccine
WHO	World Health Organization